 (Peckham et al., 1982; Horwich, 1993 
Testicular germ cell tumours are now the commonest cancer in men aged under 40 in Scotland (Sharp et al., 1993a ). The age-standardised incidence rate of testicular NSGCT in Scotland for 1988-90 was 2.3:100000, and has risen from 1.8:100000 for 1975-77 (Sharp et al., 1993b) . Effective chemotherapy has transformed what was invariably a fatal disease, once it had metastasised, to one which is usually curable (Ellis and Sikora, 1987) . Cure rates may be related to the ability to give effective treatment and it has been suggested that results are better when there is a particular exper- tise in the treatment of the disease (Harding et al., 1993) .
Orchidectomy followed by intensive surveillance, which is expensive in clinic and medical time, is now considered the accepted management for most patients with stage I teratoma (Peckham et al., 1982; Horwich, 1993) . Patients with poor prognostic histological features, and where the disease has spread beyond the testis, require cytotoxic chemotherapy. Cure rates as high as 90% can now be expected for good prognosis metastatic disease (Horwich, 1989) . There are now well-documented prognostic factors that can predict for poorer survival. The role of more intensive chemotherapy regimens for these patients has been the subject of much debate and is currently being assessed by an MRC Trial (Kaye et al., 1989) .
The importance of complete surgical excision of residual masses after chemotherapy is now accepted and surgeons experienced in this field may be more likely to perform adequate resections (Ewing et al., 1987; Hendry et al., 1987; .
Most clinicians continue to follow up intensively patients who have been treated for metastatic NSGCT. The rationale for this is that second-line chemotherapy may be curative if the disease is caught early at the time of relapse. Undoubtedly, some patients may be cured by second-line chemotherapy, but for others salvage therapy should be viewed as palliative and opinions vary as to optimal follow-up for these patients. Defaults from follow-up were recorded in 35% of patients on active surveillance and 21% of patients with posttreatment follow-up (27% for all clinic attendances). The commonest reasons recorded for defaulting were anxiety, transport difficulties and lack of finance.
There was a marked difference in the number of patients being treated in a trial setting at a time when almost all patients would have been eligible for inclusion within MRC studies. Only two of the five centres entered patients with 69% and 53% of all patients being entered by centres E and D respectively. Multiple chemotherapy regimens were used for patients with both good and poor prognostic disease. Although there will always be reasons for tailoring chemotherapy to individual patients national guidelines for first-and second-line chemotherapy for patients not entered into a trial protocol might result in a more consistent approach to the management of this disease.
The trial entry is poor for a rare tumour at a time when almost all patients woiuld have been eligible for one trial or another. There is a particularly noticeable variation in trial entry between centres. The reasons for this relate to lack of clerical and other support and this should improve following the setting up of the Scottish Cancer Therapy Network.
